Orally dissolving films

Rapidly dissolving, oral film preparations for rapid release of an active agent in the oral cavity, in particular, rapidly dissolving oral films comprising a nicotine active which achieve good transbuccal absorption and provide nicotine ...

SY Chan，LL Chen，DJ Chetty，... - US

Duloxetine Formulation

A duloxetine pellet formulation comprises: (i) a core including a desired amount of duloxetine; (ii) an enteric coating comprising hydroxypropylmethylcellulose phthalate (HPMCP) as an enteric polymer; and, optionally, (iii) a separating ...

R Sareen，PHR Persicaner - US

DNT-fumarate and methods of preparation thereof

(S)-N,N-Dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine fumarate (DNT-fumarate) and polymorphs of DNT-fumarate, compositions of DNT-fumarate and its polymorphs, processes for the preparation of DNT-fumarate and its polymorphs, an...

S Ini，A Liberman，M Abramov，... - US

Orally dissolving films

本文公开了用于在口腔中快速释放活性剂的快速溶解口腔薄膜制剂,尤其是包括能获得良好经口腔吸收并能为个体提供烟碱瘾缓解的烟碱活性物的快速溶解口腔薄膜. Disclosed...

陈成裕，陈丽兰，杜申德拉·J·切蒂，...

SEPARATING LAYERS FOR PHARMACEUTICAL PREPARATIONS TO PREVENT INTERACTIONS BETWEEN MEDICINAL DRUGS AND PHARMACEUTICAL-TECHNOLOGICAL ADJUVANTS

The invention relates to a granular pharmaceutical preparation comprising a core containing an active substance, comprising duloxetine or a pharmaceuticall...

B Schluetermann，F Gerber，A Prasch

TREATMENT OF PERSISTENT PAIN

A method of using N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine to treat persistent pain.

GD Joel，I Smriti，SRM Ademe

Controlled release dosage formulation of duloxetine

The preset invention provides a controlled release dosage form of duloxetine comprising a homogenous core comprised of duloxetine or its pharmaceutically acceptable salts, pharmaceutically acceptable polymeric carrier, solubility enhance...

PRASAD RUDRESHA KORLAKUNTE VIR，DESOMAYANANDAM PRABHAKARAN - WO

ORAL PREPARATION WITH CONTROLLED RELEASE

A pharmaceutical pellet is provided, comprising a spherical core containing the active substance with a smooth surface and a coating on the core, which controls pH-independent release of the active substance. With a pellet of this kind, ...

B Schlütermann，M Kohlmeyer - US

Duloxetine hydrochloride delayed release formulations

Delayed release formulations of duloxetine hydrochloride and methods for its manufacture are described. A preferred formulation includes an inert core, a drug layer comprising duloxetine hydrochloride, a separating layer and an enteric l...

G Kolatkar，E Zisman - WO

Pharmaceutical compositions of duloxetine

Delayed release formulations of duloxetine hydrochloride and methods for its manufacture are described. A preferred formulation includes an inert core, a drug layer comprising duloxetine hydrochloride, a separating layer and an enteric l...

RK Sheth，S Umesh，HM Patel